Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Friday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

Aptevo Therapeutics stock opened at $0.21 on Friday. The firm has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.44. Aptevo Therapeutics has a 1-year low of $0.14 and a 1-year high of $10.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.